MCRB
Seres Therapeutics, Inc.
Next earnings Aug 4, 2026 · consensus $-2.35 EPS, $365K rev
Last earnings -2.5% on 2026-05-05
$7.08
▲ +3.43%$7.08▼ -4.58%
over 1Y
L $5.62EODHDH $28.63
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.4%
1W+7.3%
1M-7.2%
3M-21.3%
YTD-53.3%
1Y-4.6%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Strong net margin (721.9%).
Revenue (FY2025) $789K · FY2025
The read
Middling fundamentals offset by an attractive price (~244% below fair value) — worth a look on the value angle.
Seres Therapeutics, Inc. shows $789K in FY2025 revenue, a 721.9% net margin, and 12.9% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $145M | $7.13M | $0.00 | $0.00 | $789K |
| Gross profit | — | — | — | — | — |
| Operating income | -$64.5M | -$180M | -$195M | -$121M | -$94.0M |
| Net income | -$65.6M | -$250M | -$114M | $136K | $5.70M |
| Diluted EPS | -$0.72 | -$2.31 | -$17.77 | $0.00 | $0.64 |
| Net margin | -45.2% | -3509.5% | — | — | 721.9% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$132M
EV / EBITDA—
EV / Sales167.4
EV / FCF152.7
P / FCF78.5
PEG (trailing)0.00
Earnings yield8.4%
FCF yield1.3%
Quality & risk
ROIC (est.)-48.1%
Free cash flow$865K
Total debt$110M
Net cash-$64.2M
Altman Z-Score-11.40 distress
Piotroski F-Score6/8
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY-94.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-022026-06-05open ↗8-KPeriod ending 2026-05-302026-06-01open ↗144Filing2026-05-19open ↗4Period ending 2026-05-152026-05-19open ↗4Period ending 2026-05-152026-05-19open ↗4Period ending 2026-05-152026-05-19open ↗4Period ending 2026-05-152026-05-19open ↗10-QPeriod ending 2026-03-312026-05-05open ↗8-KPeriod ending 2026-05-052026-05-05open ↗DEFA14AFiling2026-04-27open ↗DEF 14APeriod ending 2026-06-092026-04-27open ↗144Filing2026-03-17open ↗
Frequently asked
- Is Seres Therapeutics, Inc. (MCRB) a buy?
- MCRB currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Strong net margin (721.9%).
- What is MCRB's fair value?
- A Modified-Graham model based on MCRB's SEC fundamentals estimates a fair value of about $24.32. It is an estimate from reported earnings, not a price target.
- Is MCRB overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, MCRB currently appears undervalued relative to its SEC-grounded earnings power.
- What is Seres Therapeutics, Inc.'s quality score?
- MCRB scores 70.56862745098039/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001609809, latest 10-Q filed 2026-05-05) · EODHD · as of 6/26/2026, 7:48:47 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.